Tirzepatide is a dual GIP and GLP-1 receptor agonist licensed for type 2 diabetes treatment in the UK Brain fog does not appear in the MHRA-approved Summary of Product Characteristics as an established adverse effect Potential mechanisms include blood glucose fluctuations, reduced caloric intake, gastrointestinal symptoms affecting nutrition and sleep, or central nervous system effects Management strategies include optimising nutrition and hydration, monitoring glucose levels, prioritising sleep, and following gradual dose titration Patients should seek medical advice for severe, worsening, or persistent cognitive symptoms, or if experiencing signs of hypoglycaemia or dehydration All suspected adverse effects should be reported through the MHRA Yellow Card Scheme to support ongoing pharmacovigilance Table of Contents Understanding Mounjaro and Its Mechanism of Action Brain Fog as a Potential Side Effect: What the Evidence Shows Why Mounjaro Might Contribute to Cognitive Symptoms Managing and Reducing Brain Fog While Taking Mounjaro When to Seek Medical Advice About Cognitive Changes Scientific References Frequently Asked Questions Understanding Mounjaro and Its Mechanism of Action Mounjaro (tirzepatide) is a prescription medication licensed in the UK for the treatment of type 2 diabetes mellitus
They can help fill nutritional gaps, but they cannot replace the benefits of whole foods. The best multivitamins for GLP-1 support contain nutrients that may be difficult to get enough of when your appetite is low
You will still be able to navigate the process of obtaining the medication more effectively by being proactive in exploring your options to enhance your chances of successfully starting and maintaining your treatment
doi: 10.3389/fnagi.2021.760200 375 ZhangH.ShenH.JordanC
In lower doses, hunger suppression may not noticeably last for a whole week, even though the medication may still work in other ways
McGrane MM
